Filing Flows › Profound Medical (PROF) › R&D spending
Profound Medical (PROF) R&D spending by quarter
Profound Medical's R&D spending was $5.8M in Q3 2026 (third quarter 2026), +3% from Q2 2026. Over the last 7 quarters it ranged from $4.3M (Q4 2025) to $6.1M (Q2 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $5.8M | +3% | +7% |
| Q2 2026 | $5.7M | +7% | -7% |
| Q1 2026 | $5.3M | +23% | +9% |
| Q4 2025 | $4.3M | -21% | — |
| Q3 2025 | $5.4M | -11% | — |
| Q2 2025 | $6.1M | +27% | — |
| Q1 2025 | $4.8M | — | — |
Q3 2026 at a glance
Profound Medical, Q3 2026: revenue $9.8M (+86% year over year), operating margin -79.6%, net loss $7.7M, operating cash flow −$5.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is Profound Medical's R&D spending?
Profound Medical's R&D spending was $5.8M in Q3 2026 (third quarter 2026), +3% from Q2 2026.
How has Profound Medical's R&D spending changed?
Over the last 7 quarters it ranged from $4.3M (Q4 2025) to $6.1M (Q2 2025).